Results 81 to 90 of about 760 (154)

A 4-methyl-substituted durlobactam analogue as a potential class-D oxacillinase inhibitor in <i>Acinetobacter baumannii-</i>an <i>in silico</i> study. [PDF]

Front Bioinform
George EA, Naha A, Ramaiah S.
europepmc   +1 more source

Salvage Treatment of Ventilator-Associated Pneumonia Using Sulbactam-Durlobactam in a Preterm Neonate: A Case Report. [PDF]

Infect Dis Rep
Zivojinovic S, Prodanovic T, Prodanovic N, Medovic R, Cekerevac M, Savic D, Markovic B, Jankovic S.   +7 more
europepmc   +1 more source

In vitro activity of sulbactam/durlobactam against extensively drug-resistant Acinetobacter baumannii isolates belonging to South American major clones [PDF]

, 2021
Ana Cristina Gales, Fernanda F. Santos, Tiago B. Valiatti, Rodrigo Cayô, Carolina S. Nodari, Mariana N.L. Kurihara   +5 more
core   +1 more source

Comparative activity of sulbactam and sulbactam/durlobactam against carbapenem-resistant A. baumannii isolates producing OXA-23 or OXA-23 plus PER-1 enzymes. [PDF]

J Antibiot (Tokyo)
Mirza HC, Üsküdar Güçlü A, Ünlü S, Yalçın S.   +3 more
europepmc   +1 more source

A Novel UPLC Method for the Simultaneous Estimation of Sulbactam and Durlobactam in Pharmaceutical Dosage Form

Infectious diseases especially those associated with multidrug-resistant pathogens in critically ill patients are an area of global research and concern for healthcare professionals across both the private and public sectors. Sulbactam and Durlobactam have been approved as a combination drug, called Xacdura, recently for the treatment of hospital ...
openaire   +1 more source

Carbapenem-resistant <i>Acinetobacter baumannii</i> in resource-limited ICUs: when 'recommended therapy' is not realistically deliverable. [PDF]

JAC Antimicrob Resist
Saquib Alam M, Khatoon N.
europepmc   +1 more source

Antimicrobial activity of sulbactam-durlobactam against <i>Acinetobacter baumannii-calcoaceticus</i> complex strains causing non-respiratory and non-bloodstream infections from the United States (2023-2025). [PDF]

Microbiol Spectr
Cyr E, Argotsinger J, Beck ET, Chamberland RR, Clark AE, Daniels AR, Liesman R, Fisher M, Gialanella P, Hand J, Harrington AT, Humphries RM, Huse H, Hamilton-Seth R, Hankins JD, Kufel WD, Riddell SW, Mehta M, Demkowicz R, Mochon AB, Salimnia H, Khan A, Pierce VM, Potula R, Tekle T, Simner PJ, Tibbetts RJ, Vu C, Abbo LM, Martinez O, Dumm RE, Mutnal MB, Jenkins TC, Chávez V, Pinargote P, Bowling J, Munson E, Zurawski DV, Nicolau DP, Asempa TE, Acinetobacter baumannii Complex National Biorepository (ACNBio) Study Group.   +40 more
europepmc   +1 more source

Draft genome sequence of a KPC-2-producing, meropenem-durlobactam non-susceptible <i>Klebsiella pneumoniae</i> ST11-KL64 clinical isolate. [PDF]

Microbiol Resour Announc
Wen H, Feng Y, Zong Z.
europepmc   +1 more source

In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates. [PDF]

J Antimicrob Chemother
Patterson-Fahy K, Carter R, Bell SC, Evans IES, Burke AJ, Thomson RM.   +5 more
europepmc   +1 more source

Disarming carbapenemase-producing <i>Acinetobacter baumannii</i>: high potency of the novel therapeutic combination of meropenem and the innovative diazabicyclooctane β-lactamase inhibitor pilabactam (formerly ANT3310). [PDF]

Antimicrob Agents Chemother
Rodríguez-Pallares S, Outeda-García M, Lence E, Rodríguez-Coello A, González-Pinto L, Guijarro-Sánchez P, Báez-Barroso GA, Blanco-Martín T, Vázquez-Ucha JC, Llanos A, Sannio F, Docquier J-D, Morrisey I, Hawser S, Zalacain M, Lemonnier M, González-Bello C, Bou G, Beceiro A, Arca-Suárez J.   +19 more
europepmc   +1 more source